Adam Simpson, Icosavax CEO
Icosavax pushes forward combo RSV-hMPV vaccine and announces direct stock offering
Seattle-based Icosavax may have failed in its attempt at a Covid-19 vaccine in 2022, but it released early data on its bivalent vaccine candidate for RSV and human metapneumovirus (hMPV) — and announced a $67.8 million direct offering of its common stock yesterday.
The vaccine candidate for older adults, dubbed IVX-A12 and granted fast track designation by the FDA, is made up of the company’s RSV and hMPV vaccines. The bivalent vaccine could potentially take meaningful market share in a future ~$10 billion+ market.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters